Telix Pharmaceuticals Ltd (TLX)

Sydney
Currency in AUD
26.840
+0.350(+1.32%)
Closed
TLX Scorecard
Full Analysis
Net income is expected to grow this year
Trading near 52-week High
Fair Value
Day's Range
26.59027.150
52 wk Range
10.33527.150
Key Statistics
Edit
Bid/Ask
26.70 / 26.97
Prev. Close
26.49
Open
26.62
Day's Range
26.59-27.15
52 wk Range
10.335-27.15
Volume
1.18M
Average Volume (3m)
953.82K
1-Year Change
142.12%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TLX Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
24.768
Downside
-7.72%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth
Show more

Telix Pharmaceuticals Ltd Company Profile

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.

Compare TLX to Peers and Sector

Metrics to compare
TLX
Peers
Sector
Relationship
P/E Ratio
182.7x−2.7x−0.6x
PEG Ratio
0.91−0.020.00
Price/Book
22.2x2.4x2.6x
Price / LTM Sales
13.9x10.0x3.1x
Upside (Analyst Target)
−10.2%293.0%50.2%
Fair Value Upside
Unlock3.0%7.5%Unlock

Analyst Ratings

6 Buy
1 Hold
1 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 24.768
(-7.72% Downside)

Earnings

Latest Release
Oct 17, 2024
EPS / Forecast
-- / --
Revenue / Forecast
201.00M / 151.80M
EPS Revisions
Last 90 days

FAQ

What Is the Telix Pharma (TLX) Stock Price Today?

The Telix Pharma stock price today is 26.84

What Stock Exchange Does Telix Pharma Trade On?

Telix Pharma is listed and trades on the Sydney stock exchange.

What Is the Stock Symbol for Telix Pharma?

The stock symbol for Telix Pharma is "TLX."

What Is the Telix Pharma Market Cap?

As of today, Telix Pharma market cap is 8.95B.

What is Telix Pharma Earnings Per Share?

The Telix Pharma EPS is 0.152.

What Is the Next Telix Pharma Earnings Date?

Telix Pharma will release its next earnings report on 18 Feb 2025.

From a Technical Analysis Perspective, Is TLX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.